Skip to main content
Terug
IDYA logo

IDEAYA Biosciences, Inc.

Datakwaliteit: 100%
IDYA
NASDAQ Healthcare Biotechnology
€ 30,53
▼ € 1,11 (-3,51%)
Marktkapitalisatie: 2,68B
Dagbereik
€ 29,57 € 31,53
52-Weeksbereik
€ 13,45 € 39,28
Volume
1.000.774
50D / 200D Gem.
€ 33,65 / € 29,03
Vorige Slotkoers
€ 31,64

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -23,6 0,4
P/B 2,6 2,9
ROE % -10,9 3,9
Net Margin % -52,0 3,8
Rev Growth 5Y % 67,3 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 46,75 +53.1%
Low: € 30,00 High: € 60,00
Forward WPA
-€ 3,97
Omzet Sch.
36 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 2,07
€ 0,19 – € 4,74
990 M 4
FY2029 -€ 0,65
-€ 1,48 – -€ 0,06
570 M 4
FY2028 -€ 2,44
-€ 4,01 – € 0,80
280 M 10

Belangrijkste Punten

Revenue grew 67,27% annually over 5 years — strong growth
Debt/Equity of 0,03 — conservative balance sheet
Negative free cash flow of -73,47M
PEG of 0,43 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 2957,16%
Capital efficient — spends only 1,08% of revenue on capex

Groei

Revenue Growth (5Y)
67,27%
Revenue (1Y)3024,43%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-10,92%
ROIC-11,37%
Net Margin-51,99%
Op. Margin-72,84%

Veiligheid

Debt / Equity
0,03
Current Ratio11,34
Interest Coverage0,00

Waardering

P/E Ratio
-23,58
P/B Ratio2,62
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3024,43% Revenue Growth (3Y) 205,82%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 67,27% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 218,71M Net Income (TTM) -113,70M
ROE -10,92% ROA -10,25%
Gross Margin 97,90% Operating Margin -72,84%
Net Margin -51,99% Free Cash Flow (TTM) -73,47M
ROIC -11,37% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 11,34
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -23,58 P/B Ratio 2,62
P/S Ratio 12,26 PEG Ratio 0,43
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,68B Enterprise Value 2,60B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 218,71M 7,00M 23,39M 50,93M 27,94M
Net Income -113,70M -274,48M -112,96M -58,66M -49,76M
EPS (Diluted) -1,28 -3,36 -1,96 -1,42 -1,41
Gross Profit 214,12M 3,17M 19,38M 48,83M 26,22M
Operating Income -159,31M -326,98M -134,43M -62,50M -50,27M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,11B 1,12B 649,32M 387,97M 381,35M
Total Liabilities 86,39M 64,94M 28,23M 38,51M 79,83M
Shareholders' Equity 1,02B 1,06B 621,09M 349,46M 301,51M
Total Debt 27,91M 19,17M 2,87M 3,48M 5,18M
Cash & Equivalents 112,83M 84,38M 157,02M 68,63M 92,05M
Current Assets 666,73M 689,71M 532,63M 370,45M 251,00M
Current Liabilities 58,82M 46,07M 27,10M 31,72M 45,16M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#30 of 146
61

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026